Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focusing on AAV-based gene therapies for CNS diseases, has announced the granting of stock options to two new employees. The Compensation Committee approved options to purchase 356,000 shares of common stock on August 1, 2024, under the company's 2023 Inducement Plan. These options, granted in accordance with Nasdaq Listing Rule 5635(c)(4), have an exercise price of $2.16 per share, equal to the closing price on the grant date. The options have a 10-year term and will vest over four years, with 25% vesting after one year and the remaining 75% vesting monthly over the following 36 months, subject to continued employment.
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), un'azienda di biotecnologia in fase clinica focalizzata su terapie geniche basate su AAV per malattie del SNC, ha annunciato l'assegnazione di opzioni su azioni a due nuovi dipendenti. Il Comitato per la Compensazione ha approvato opzioni per acquistare 356.000 azioni ordinarie il 1° agosto 2024, nell'ambito del Piano di Induzione 2023 dell'azienda. Queste opzioni, concesse in conformità alla regola di quotazione Nasdaq 5635(c)(4), hanno un prezzo di esercizio di $2,16 per azione, uguale al prezzo di chiusura alla data di concessione. Le opzioni hanno un termine di 10 anni e acquisiranno valore in quattro anni, con il 25% che matura dopo un anno e il restante 75% che matura mensilmente nei successivi 36 mesi, a condizione di continuare l'impiego.
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), una empresa de biotecnología en etapa clínica centrada en terapias génicas basadas en AAV para enfermedades del SNC, ha anunciado la concesión de opciones sobre acciones a dos nuevos empleados. El Comité de Compensación aprobó opciones para adquirir 356,000 acciones ordinarias el 1 de agosto de 2024, bajo el Plan de Inducción 2023 de la empresa. Estas opciones, otorgadas de acuerdo con la regla de cotización Nasdaq 5635(c)(4), tienen un precio de ejercicio de $2.16 por acción, igual al precio de cierre en la fecha de concesión. Las opciones tienen un plazo de 10 años y se consolidarán durante cuatro años, con el 25% consolidándose después de un año y el 75% restante consolidándose mensualmente durante los siguientes 36 meses, sujeto a la continuidad del empleo.
Taysha Gene Therapies, Inc. (Nasdaq: TSHA)는 CNS 질환을 위한 AAV 기반 유전자 치료에 중점을 두고 있는 임상 단계의 바이오 제약 회사로, 두 명의 신입 직원에게 주식 옵션을 부여한다고 발표했습니다. 보상위원회는 2024년 8월 1일 회사의 2023 유도 계획에 따라 356,000주의 보통주를 매입할 수 있는 옵션을 승인했습니다. 이 옵션은 Nasdaq 상장 규정 5635(c)(4)에 따라 부여되며, 부여일의 종가와 동일한 주당 $2.16의 행사가격을 가지고 있습니다. 옵션의 유효기간은 10년이며, 4년에 걸쳐 분할하여 행사됩니다. 1년 후 25%가 행사되며, 나머지 75%는 향후 36개월 동안 매달 행사됩니다. 단, 계속해서 재직해야 합니다.
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), une entreprise de biotechnologie en phase clinique axée sur les thérapies géniques basées sur AAV pour les maladies du système nerveux central, a annoncé l'octroi d'options d'achat d'actions à deux nouveaux employés. Le Comité de Rémunération a approuvé des options d'achat de 356 000 actions ordinaires le 1er août 2024, selon le Plan d'Induction 2023 de l'entreprise. Ces options, accordées conformément à la règle de cotation 5635(c)(4) de Nasdaq, ont un prix d'exercice de 2,16 $ par action, égal au prix de clôture en date d'octroi. Les options ont une durée de 10 ans et seront acquises sur quatre ans, avec 25 % acquises après un an et les 75 % restants acquises mensuellement au cours des 36 mois suivants, sous réserve du maintien de l'emploi.
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf AAV-basierte Gentherapien für Erkrankungen des zentralen Nervensystems spezialisiert hat, hat die Gewährung von Aktienoptionen an zwei neue Mitarbeiter angekündigt. Der Vergütungsausschuss genehmigte Optionen zum Kauf von 356.000 Aktien am 1. August 2024 im Rahmen des Unternehmensplans zur Induktion 2023. Diese Optionen, die gemäß der Nasdaq-Listing-Regel 5635(c)(4) gewährt wurden, haben einen Ausübungspreis von 2,16 $ pro Aktie, der dem Schlusskurs am Tag der Gewährung entspricht. Die Optionen haben eine Laufzeit von 10 Jahren und werden über vier Jahre fällig, wobei 25% nach einem Jahr und die verbleibenden 75% monatlich über die folgenden 36 Monate fällig werden, vorausgesetzt, die Beschäftigung wird kontinuierlich fortgeführt.
- Stock options granted as inducement for new employees, potentially attracting talent
- Options have a 10-year term, providing long-term incentive for employee retention
- Potential dilution of existing shareholders' equity due to new stock options
DALLAS, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on August 1, 2024, the Compensation Committee of Taysha's Board of Directors granted two new employees, in the aggregate, options to purchase 356,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.
Company Contact:
Hayleigh Collins
Director, Head of Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com
Media Contact:
Carolyn Hawley
Inizio Evoke
Carolyn.hawley@inizioevoke.com
FAQ
How many shares of TSHA stock options were granted to new employees?
What is the exercise price of the TSHA stock options granted on August 1, 2024?
What is the vesting schedule for the TSHA stock options granted to new employees?
Under which plan were the TSHA stock options granted to new employees?
